Regdanvimab improves disease mortality and morbidity in patients with COVID-19 : A meta-analysis
| Errataetall: |
CommentOn: J Infect. 2022 Jun;84(6):834-872. - PMID 35301014 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:85 |
|---|---|
| Enthalten in: |
The Journal of infection - 85(2022), 4 vom: 01. Okt., Seite e122-e124 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Mingyang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 13.09.2022 Date Revised 21.08.2023 published: Print-Electronic CommentOn: J Infect. 2022 Jun;84(6):834-872. - PMID 35301014 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2022.05.044 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342498258 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342498258 | ||
| 003 | DE-627 | ||
| 005 | 20231226014244.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2022.05.044 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342498258 | ||
| 035 | |a (NLM)35728643 | ||
| 035 | |a (PII)S0163-4453(22)00369-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Mingyang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Regdanvimab improves disease mortality and morbidity in patients with COVID-19 |b A meta-analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.09.2022 | ||
| 500 | |a Date Revised 21.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: J Infect. 2022 Jun;84(6):834-872. - PMID 35301014 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Regdanvimab | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a regdanvimab |2 NLM | |
| 650 | 7 | |a I0BGE6P6I6 |2 NLM | |
| 700 | 1 | |a Li, Toni |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Lihai |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yushu |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Carolyn |e verfasserin |4 aut | |
| 700 | 1 | |a Ao, Guangyu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 85(2022), 4 vom: 01. Okt., Seite e122-e124 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:85 |g year:2022 |g number:4 |g day:01 |g month:10 |g pages:e122-e124 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2022.05.044 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 85 |j 2022 |e 4 |b 01 |c 10 |h e122-e124 | ||